trial

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

NCTId NCT06058702
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 215 (estimated)
Sponsored by Yale University
Primary completion 2028-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
215 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2024-09-16
Primary completion
2028-12-31
Eligibility
ALL · 21 Years · 60 Years

Interventions & indications

Drugs
Delta-9-THC Very Low DoseDelta-9-THC Medium Dose

Sponsors

Yale UniversityLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Deepak Cyril D'Souza, MDPrincipal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
215
Phase
PHASE1
Primary Completion Date
2028-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Delta-9-THC Very Low Dose
drug
Delta-9-THC Medium Dose
drug
lead_sponsor
Yale University
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cannabis Use Disorder
indication
investigator
Deepak Cyril D'Souza, MD
person